676560-26-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzonitrile, 4-[(trans-4-aminocyclohexyl)oxy]is used as a chemical intermediate for the synthesis of pharmaceutical drugs. Its unique structure allows it to be incorporated into various drug molecules, potentially enhancing their therapeutic properties and efficacy.
Used in Agrochemical Industry:
Benzonitrile, 4-[(trans-4-aminocyclohexyl)oxy]is used as a chemical intermediate in the synthesis of agrochemicals. Its incorporation into agrochemical compounds may improve their effectiveness in pest control and crop protection.
Used in Organic Synthesis:
Benzonitrile, 4-[(trans-4-aminocyclohexyl)oxy]is used as a reagent in organic synthesis. Its versatile structure allows it to be used in various chemical reactions, facilitating the synthesis of a wide range of organic compounds for different applications.

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 27489-62-9 trans-4-hydroxycyclohexylamine 

Downstream Products

• 1394012-10-2 4-(((1r,4r)-4-aminocyclohexyl)oxy)benzoic acid 
• 1394012-06-6 trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-N-methylbenzamide 

Relevant academic research and scientific papers

Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response

Heme-regulated inhibitor (HRI), an eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, plays critical roles in cell proliferation, differentiation, adaptation to stress, and hemoglobin disorders. HRI phosphorylates eIF2α, which couples cellular signals, including endoplasmic reticulum (ER) stress, to translation. We previously identified 1,3-diarylureas and 1-((1,4-trans)-4-aryloxycyclohexyl)-3-arylureas (cHAUs) as specific activators of HRI that trigger the eIF2α phosphorylation arm of ER stress response as molecular probes for studying HRI biology and its potential as a druggable target. To develop drug-like cHAUs needed for in vivo studies, we undertook bioassay-guided structure-activity relationship studies and tested them in the surrogate eIF2α phosphorylation and cell proliferation assays. We further evaluated some of these cHAUs in endogenous eIF2α phosphorylation and in the expression of the transcription factor C/EBP homologous protein (CHOP) and its mRNA, demonstrating significantly improved solubility and/or potencies. These cHAUs are excellent candidates for lead optimization for development of investigational new drugs that potently and specifically activate HRI.

Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition.

SORAFENIB DERIVATIVES AS sEH INHIBITORS

The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.